First Week of IMNM February 2026 Options Trading

Immunome (IMNM) trades at $20.45 while a put at the $18 strike bids $0.20, which would set an effective purchase basis of $17.80 and is ~12% out-of-the-money; analytics assign a ~70% probability it expires worthless, yielding 1.11% (6.44% annualized) on the cash commitment. On the call side, a $21 strike bids $1.55; selling the covered call against stock bought at $20.45 would produce a 10.27% total return if called at the Feb 2026 expiration, with a 43% chance of expiring worthless and a 7.58% premium boost (43.91% annualized). Implied volatilities are elevated (put 118%, call 99%) versus trailing 12-month volatility of 78%, making these income-oriented option trades attractive to yield-seeking investors but leaving substantial upside risk if shares rally.

Analysis

Market structure: The immediate winners are option premium sellers and yield-seeking income strategies — selling the IMNM Feb‑2026 $18 put nets $0.20 (cost basis $17.80) and selling the $21 call nets $1.55 while capping upside; market-makers and volatility sellers collect rich premia (put IV 118% vs realized 78%). Demand for downside protection (high put IV) signals asymmetric tail fear vs limited upside interest (call IV 99%), implying flow-driven skew rather than pure fundamentals. Cross-asset: a negative clinical event would widen biotech credit spreads and press XBI/IBB lower, while risk-off would bid US Treasury safe-haven yields down; FX/commodities largely unaffected absent systemic shock.

Risk assessment: Tail risks are classic biotech: clinical/FDA failure, near-term equity raises (secondary offerings) and sudden IV explosions — any S‑3 or 8‑K within 90 days raises dilution risk materially. Time horizons: immediate (days) — liquidity and option order flow; short-term (weeks/months) — readouts/financings that can move IV >50 pts; long-term (to Feb‑2026) — secular business outcomes and potential multiple expansion or collapse. Hidden dependencies include skewed retail/hedge fund positioning and block trades that can flip implied odds quickly; monitor IV spikes above 150% as a practical danger threshold.

Trade implications: Tactical direct plays: (A) Cash‑secured short put: sell IMNM Feb‑2026 $18 put, sizing 1–3% portfolio, target net basis $17.80, hedge with buy $15 put for defined-risk spread if >1% allocation; exit if IV >130% or price < $16. (B) Covered call: if long IMNM at ~$20.45, sell $21 call to get ~10% return to Feb‑2026; roll or buy back if price >$23 or IV >120. Pair trade: long IMNM / short XBI to neutralize sector beta (start 0.5:1 size, rebalance monthly).

Contrarian angles: The market may be underpricing assignment/dilution risk — 70% odds of put expiring worthless still imply a 30% chance of material drop, so short‑vol strategies are asymmetrically risky. Historical parallels (small biotech secondary after IV spike) show >30% permanent downmoves; conversely if no binary events, mean reversion of IV (78% realized vs 100–118% implied) could favor selling premium selectively. Unintended consequences: early exercise, forced assignment into illiquid stock, or an opportunistic secondary within 60–90 days can turn an income trade into a long-term equity holding with >25% downside.

Key Decisions for Investors

• Establish a cash‑secured short put position: sell IMNM Feb‑2026 $18 put for $0.20 sized at 1–3% of portfolio, target effective entry cost $17.80; protect downside by buying the $15 put (buy‑sell put spread) if the position exceeds 1% allocation or if IV drops below 90% to lock defined risk.
• If already long IMNM (~$20.45), sell the Feb‑2026 $21 covered call to collect $1.55 (projected 10.3% to assignment); set automatic buyback if IMNM > $23 or if IV >120% to avoid excessive short‑vol exposure.
• Implement a sector‑hedged pair: go long IMNM and short 0.5x–1.0x exposure to XBI (SPDR S&P Biotech ETF) to isolate idiosyncratic outcome; rebalance monthly and close if IMNM outperforms by >20% or if XBI underperforms by >15.
• Avoid naked short‑vol positions >3% portfolio: monitor for S‑3/8‑K filings and any clinical readout dates over the next 90 days; if an S‑3 is filed or IV >150%, unwind or convert to defined‑risk spreads immediately.